Biotechnology

A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%

PARIS, Sept. 18, 2026 /PRNewswire/ --  Virbac Headquarters, Carros, France * H1 2026 delivered a robust revenue growth of +7.4% and an adjusted EBIT margin of 18.8% at CERS: ○  Revenue growth is coming from both segm...

2026-09-18 00:33 2443

New Peer-Reviewed Study Confirms Innovative Technology Shatters ESR's Four-Hour Deadline

ALCOR Scientific's iSED® analyzers reshape lab logistics and improve patient care for one of medicine's most widely used tests * Seven times longer stability, independently validated. ESR samples on ALCOR Scientific's iSED analyzer remained accurate for up to 28 hours at room temperature and 4...

2026-09-17 21:00 2166

Dr. Alison Armour agrees to become Chief Medical Officer of Alpha Fusion, as Company Advances Integration of At-211 Businesses with Curadh MTR

— Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company — TOKYO, Sept. 17, 2026 /PRNewswire/ -- Alpha Fusion Inc. ("Alpha Fusion"), a clinical-stage company with an advanced At-211 drug platform, and Curadh ...

2026-09-17 19:00 2464

WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development

SHANGHAI, Sept. 17, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced an out-licensing collab...

2026-09-17 16:09 2711

Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs

22 researchers honored for Nobel-class discoveries, including pioneers of GLP-1 medicines and other world-changing advances LONDON, Sept. 17, 2026 /PRNewswire/ -- Clarivate Plc ...

2026-09-17 15:05 2525

111, Inc. Announces Second Quarter 2026 Unaudited Financial Results

* Transition from An Asset-Heavy Business Model to An Asset-Light Business Model * Ongoing Investment and Adoption of AI Agents Making Workforce Streamlining Possible * Net Revenue of Promotional Products (1) Increased by 121% and Gross Profit Rose by 120% Year-over-Year * Total Marketpla...

2026-09-17 15:00 6792

Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate

HONG KONG, Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluatio...

2026-09-17 14:34 1933

OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody

* Cesalatamig is Currently Being Evaluated in Phase 1/2 Studies in the United States (NCT06635785 ) and in China (CTR20253261

2026-09-16 19:00 2330

Nona Biosciences Successfully Develops World's First Language Model Trained on Fully Human Heavy-Chain-Only Antibodies

CAMBRIDGE, Mass., Sept. 16, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced the development of HCAbLM, the world's first language model specifically trained on ful...

2026-09-16 18:01 2091

WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership

SHANGHAI, Sept. 16, 2026 /PRNewswire/ -- Forbes China recently released the 2026 Forbes China ESG 50 list. WuXi Biologics was named to the list for its outstanding performance in sustainable development, Green CRDMO solutions and ESG digital innovation, and was highlighted by Forbes China as one ...

2026-09-16 16:57 2538

GHIT Fund Launches "NTDpedia" to Help Turn Apathy Into Action Against Neglected Tropical Diseases

The interactive educational website makes NTDs understandable to a general audience, the first step toward public support that drives R&D for the 1.5 billion people affected by these diseases TOKYO, Sept. 16, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced the ...

2026-09-16 13:00 1699

Ferronova announces preliminary results of MAGMAP, a 62-patient gastric and oesophageal cancer trial investigating lymph node mapping

KYOTO, Japan, Sept. 16, 2026 /PRNewswire/ -- Australian medical technology company Ferronova has announced preliminary findings from the MAGMAP multi-centre trial involving 62 gastric and oesophageal patients evaluating the safety and feasibility of a new nanoparticle-based platform to assist cl...

2026-09-16 12:00 2560

Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients

* The fifteen-month dataset represents the final analysis from the Phase 1/2 study * At the Month 15 primary timepoint, SKY-0515-treated patients showed a +1.59-point difference in Composite Unified Huntington's Disease Rating Scale (cUHDRS) change from baseline versus overlap-weighted extern...

2026-09-16 00:58 2935

Minesto presents today at Aktiedagen i Stockholm

GOTHENBURG, Sweden, Sept. 16, 2026 /PRNewswire/ -- Minesto's CEO Dr Martin Edlund presents today at Aktiedagen i Stockholm by Aktiespararna, 15 September 2026 The event is livestreamed, and Minesto will be presenting at 18.30 CEST:  Aktiespararna

2026-09-16 00:31 2437

CordenPharma Appoints Dr. Jean-Luc Herbeaux as Chief Executive Officer to Lead Next Phase of Growth

* Dr. Jean-Luc Herbeaux appointed Chief Executive Officer of CordenPharma, effective 1 October 2026   * Dr. Michael Quirmbach to transition from President & CEO to Board Member and Senior Advisor, remaining actively involved with CordenPharma   * Planned leadership transition builds on 12 ye...

2026-09-15 22:30 2786

Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society

* Late-Breaking selection at the 31st Annual World Muscle Society Congress — a designation reserved for findings the program committee determines to be of immediate importance to the field * Presentation expected to provide the first clinical evidence that a small activating RNA (saRNA) can u...

2026-09-15 22:19 3263

Xylo Bio Achieves Clinical-Stage Milestone with XYL-1001, a Highly Selective Neuroplastogen Targeting Major Depressive Disorder

BOSTON, Sept. 15, 2026 /PRNewswire/ -- Xylo Bio, a clinical-stage biotechnology company developing novel neurotherapeutics for psychiatric and neurological disorders, today announced the first participants dosed in its Phase 1 clinical study of XYL-1001, a novel, selective 5-HT2A agonist being de...

2026-09-15 18:00 1845

Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026

HONG KONG, Sept. 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organ...

2026-09-15 14:14 2317

5th Hong Kong International Biotechnology Conference and Exhibition (BIOHK2026) Officially Opens

HONG KONG, Sept. 11, 2026 /PRNewswire/ -- Hong Kong International Biotechnology Conference and Exhibition (BIOHK2026) officially opened on September 9, 2026, at the Hong Kong Convention and Exhibition Centre. Marking a key 5-year milestone, this flagship life sciences event connects Hong Kong, Ma...

2026-09-15 13:58 1756

REJURAN® COSMETICS Brings K-Beauty to LAFC Korean Heritage Night as Proud Skincare Partner

Korea's original PDRN brand connected with Los Angeles football fans through product sampling and creator experiences LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- REJURAN® COSMETICS, Korea's original PDRN brand from PharmaResearch, joined LAFC's Korean Heritage Night on Wednesday, Sept. 9, as a P...

2026-09-14 23:07 2532
1 ... 3456789 ... 356